Ultralife Corporation (ULBI)
After hours:
| Previous close | 11.70 |
| Open | 11.68 |
| Bid | 11.82 x 100 |
| Ask | 12.06 x 100 |
| Day's range | 11.22 - 12.00 |
| 52-week range | 3.92 - 12.22 |
| Volume | |
| Avg. volume | 80,849 |
| Market cap | 197.105M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 18.70 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Ultralife Corporation Reports First Quarter Results
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quart
- GlobeNewswire
Ultralife Corporation to Report First Quarter Results on April 25, 2024
NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conf
- GlobeNewswire
Ultralife Corporation Reports Fourth Quarter Results
NEWARK, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: Sales of $44.5 million representing a 23.4% year-over-year increaseHighest medical sales quarter in Company’s historyOperating income of $3.6 million versus $0.2 million for the 2022 fourth quarterAdjusted EPS of $0.18 compared to a loss of $0.03 for the 2022 fourth quarterAdjusted EBITDA of $4.8 m
